Clinical Trials Sponsored by Adamas+Pharmaceuticals%2C+Inc.

Total 12 results

Adamas Pharmaceuticals, Inc.

Terminated

Efficacy and Safety of Amantadine Hydrogen Chloride (HCl) ER Tablets in Parkinson's Disease Subjects With LID (ALLAY-LID-II)

Parkinson's Disease | Levodopa Induced Dyskinesia (LID)

France, Germany, Canada, United States, Spain
Adamas Pharmaceuticals, Inc.

Terminated

Efficacy and Safety of Amantadine Hydrochloride (HCl) ER Tablets to Treat Parkinson's Disease Patients With LID. (ALLAY-LID-I)

Parkinson's Disease | Levodopa Induced Dyskinesias (LID)

France, Spain, Germany, Canada, United States
Adamas Pharmaceuticals, Inc.

Completed

Open-Label Safety Study of ADS-5102 in PD Patients With LID

Parkinson's Disease (PD) | Dyskinesia | Levodopa Induced Dyskinesia (LID)

France, Spain, United States, Canada, Germany, Austria
Adamas Pharmaceuticals, Inc.

Completed

ADS-5102 for the Treatment of Levodopa Induced Dyskinesia (EASE LID Study) (EASE LID)

Parkinson's Disease | Dyskinesia | Levodopa Induced Dyskinesia (LID)

United States, Canada
Adamas Pharmaceuticals, Inc.

Completed

Safety and Efficacy of ADS-5102 in Patients With Multiple Sclerosis and Walking Impairment

Multiple Sclerosis | Walking Impairment

United States
Adamas Pharmaceuticals, Inc.

Completed

A Safety and Efficacy Study of ADS-5102 in Patients With Multiple Sclerosis and Walking Impairment

Multiple Sclerosis | Walking Impairment

United States, Canada
Adamas Pharmaceuticals, Inc.

Completed

Safety and Efficacy of ADS-5102 in Multiple Sclerosis Patients With Walking Impairment

Multiple Sclerosis | Walking Impairment

United States, Canada
Adamas Pharmaceuticals, Inc.

Completed

Efficacy and Safety Study of ADS-5102 in PD Patients With Levodopa-Induced Dyskinesia (EASE LID 3)

Parkinson's Disease (PD) | Dyskinesia | Levodopa-Induced Dyskinesia (LID)

France, Spain, United States, Germany, Austria
Adamas Pharmaceuticals, Inc.

Completed

Oral Triple Combination Antiviral Drug Therapy for Treatment of Influenza A in Immunocompromised Subjects (PO206)

Influenza

United States, Australia, Canada, Netherlands, Singapore
Adamas Pharmaceuticals, Inc.

Completed

Extended Release Amantadine Safety and Efficacy Study in Levodopa-Induced Dyskinesia (EASED Study) (EASED)

Parkinson's Disease | Dyskinesia | Levodopa Induced Dyskinesia

United States
Oregon Health and Science University
Adamas Pharmaceuticals, Inc.

Recruiting

Effect of GOCOVRI (Amantadine, Extended Release Capsules) on Gait in Parkinson's Disease

Parkinson Disease

United States
AlaMab Therapeutics (Shanghai) Inc.
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Not yet recruiting

A Study to Evaluate the Safety and Efficacy of ALMB-0168 in Patients With Osteosarcoma

Osteosarcoma

Clinical Trials Sponsored by Adamas+Pharmaceuticals%2C+Inc.

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Sweden

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations